STOCK TITAN

[SCHEDULE 13D/A] Polestar Automotive Holding UK PLC Class C-1 ADS (ADW) SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

United Therapeutics Corp. (UTHR) – Form 144 filing. Director-level insider Paul Mahon has filed to sell an additional 11,000 common shares on or about 24 Jul 2025 through Morgan Stanley Smith Barney. At the indicated market value of $3.35 million, the block equals roughly 0.024 % of the 45.1 million shares outstanding.

The filing also discloses recent insider dispositions totaling 66,000 shares over the past three months, generating $19.56 million in gross proceeds. Including the planned sale, Mahon’s cumulative dispositions would reach 77,000 shares, or ~0.17 % of shares outstanding. All shares derive from stock-option exercises paid in cash.

No company financials are provided; the document is strictly a notice required by Rule 144. While the absolute share count is modest, continued insider selling may attract investor attention. The filing confirms regulatory compliance and does not assert possession of undisclosed adverse information.

United Therapeutics Corp. (UTHR) – Deposito Modulo 144. L'insider a livello direttivo Paul Mahon ha presentato la richiesta di vendere ulteriori 11.000 azioni ordinarie intorno al 24 luglio 2025 tramite Morgan Stanley Smith Barney. Al valore di mercato indicato di 3,35 milioni di dollari, il blocco rappresenta circa il 0,024% delle 45,1 milioni di azioni in circolazione.

Il deposito rivela inoltre cessioni recenti da parte dell'insider per un totale di 66.000 azioni negli ultimi tre mesi, generando 19,56 milioni di dollari di proventi lordi. Includendo la vendita pianificata, le cessioni cumulative di Mahon raggiungerebbero 77.000 azioni, ovvero circa lo 0,17% delle azioni in circolazione. Tutte le azioni derivano da esercizi di stock option pagati in contanti.

Non sono forniti dati finanziari dell'azienda; il documento è esclusivamente una notifica richiesta dalla Regola 144. Sebbene il numero assoluto di azioni sia modesto, la continua vendita da parte degli insider potrebbe attirare l'attenzione degli investitori. Il deposito conferma la conformità normativa e non indica il possesso di informazioni negative non divulgate.

United Therapeutics Corp. (UTHR) – Presentación del Formulario 144. El insider a nivel directivo Paul Mahon ha presentado la solicitud para vender 11,000 acciones comunes adicionales alrededor del 24 de julio de 2025 a través de Morgan Stanley Smith Barney. Al valor de mercado indicado de 3.35 millones de dólares, el bloque representa aproximadamente el 0.024% de las 45.1 millones de acciones en circulación.

La presentación también revela disposiciones recientes de insider que suman 66,000 acciones en los últimos tres meses, generando 19.56 millones de dólares en ingresos brutos. Incluyendo la venta planeada, las disposiciones acumuladas de Mahon alcanzarían 77,000 acciones, o aproximadamente el 0.17% de las acciones en circulación. Todas las acciones provienen de ejercicios de opciones sobre acciones pagados en efectivo.

No se proporcionan estados financieros de la empresa; el documento es estrictamente un aviso requerido por la Regla 144. Aunque el número absoluto de acciones es modesto, la continua venta por parte del insider podría atraer la atención de los inversores. La presentación confirma el cumplimiento regulatorio y no indica la posesión de información adversa no divulgada.

United Therapeutics Corp. (UTHR) – Form 144 제출. 임원급 내부자 Paul Mahon이 Morgan Stanley Smith Barney를 통해 2025년 7월 24일경 추가로 11,000 보통주를 매도할 계획을 제출했습니다. 표시된 시가 총액인 335만 달러 기준으로, 해당 주식 블록은 전체 4,510만 주 중 약 0.024%에 해당합니다.

이 제출서류는 또한 최근 3개월 동안 내부자가 총 66,000주를 처분하여 1,956만 달러의 총 수익을 올린 사실도 공개합니다. 계획된 매도를 포함하면 Mahon의 누적 처분 주식은 77,000주, 즉 발행 주식의 약 0.17%에 달합니다. 모든 주식은 현금으로 결제된 스톡옵션 행사에서 나온 것입니다.

회사 재무정보는 제공되지 않았으며, 이 문서는 규칙 144에 따라 요구되는 통지에 불과합니다. 절대 주식 수는 적지만, 내부자의 지속적인 매도는 투자자의 관심을 끌 수 있습니다. 이 제출은 규제 준수를 확인하며 미공개 불리한 정보 보유를 주장하지 않습니다.

United Therapeutics Corp. (UTHR) – Dépôt du formulaire 144. L'initié de niveau directeur Paul Mahon a déposé une demande pour vendre 11 000 actions ordinaires supplémentaires aux alentours du 24 juillet 2025 via Morgan Stanley Smith Barney. À la valeur marchande indiquée de 3,35 millions de dollars, ce bloc représente environ 0,024 % des 45,1 millions d'actions en circulation.

Le dépôt révèle également des cessions récentes d'initiés totalisant 66 000 actions au cours des trois derniers mois, générant 19,56 millions de dollars de produits bruts. En incluant la vente prévue, les cessions cumulées de Mahon atteindraient 77 000 actions, soit environ 0,17 % des actions en circulation. Toutes les actions proviennent d'exercices d'options sur actions payés en espèces.

Aucun état financier de la société n'est fourni ; le document est strictement un avis requis par la règle 144. Bien que le nombre absolu d'actions soit modeste, la poursuite des ventes d'initiés pourrait attirer l'attention des investisseurs. Le dépôt confirme la conformité réglementaire et ne prétend pas détenir d'informations défavorables non divulguées.

United Therapeutics Corp. (UTHR) – Form 144 Einreichung. Der Insider auf Direktorenebene, Paul Mahon, hat die Anmeldung eingereicht, um zusätzlich 11.000 Stammaktien etwa am 24. Juli 2025 über Morgan Stanley Smith Barney zu verkaufen. Zum angegebenen Marktwert von 3,35 Millionen US-Dollar entspricht dieses Paket etwa 0,024 % der 45,1 Millionen ausstehenden Aktien.

Die Einreichung offenbart auch kürzliche Insider-Veräußerungen von insgesamt 66.000 Aktien in den letzten drei Monaten, die Bruttoerlöse von 19,56 Millionen US-Dollar generierten. Einschließlich des geplanten Verkaufs würden Mahons kumulative Veräußerungen 77.000 Aktien erreichen, was etwa 0,17 % der ausstehenden Aktien entspricht. Alle Aktien stammen aus bar bezahlten Aktienoptionsausübungen.

Es werden keine Unternehmensfinanzdaten bereitgestellt; das Dokument ist ausschließlich eine gemäß Regel 144 erforderliche Mitteilung. Obwohl die absolute Stückzahl gering ist, könnte der fortgesetzte Insider-Verkauf die Aufmerksamkeit der Investoren auf sich ziehen. Die Einreichung bestätigt die Einhaltung der Vorschriften und behauptet nicht, über nicht veröffentlichte nachteilige Informationen zu verfügen.

Positive
  • Regulatory compliance: Filing under Rule 144 signals adherence to disclosure requirements, mitigating legal risk.
Negative
  • Continued insider selling: Aggregate 77,000 shares scheduled or sold in three months may be perceived as a bearish sentiment indicator.
  • Lack of offsetting insider buys: No purchases disclosed to counterbalance the disposals.

Insights

TL;DR: Small—0.024 %—insider sale; ongoing disposals worth $23 m YTD could be viewed as mild negative but not financially material.

The proposed 11,000-share sale adds to a 66,000-share disposal history over the last quarter. Even combined, the 77,000 shares equal just 0.17 % of UTHR’s float, limiting dilution or ownership impact. Insider sales may hint at reduced personal conviction, yet the transactions stem from option exercises, a common liquidity event. No operational data accompany the notice, so fundamental outlook remains unchanged. Overall impact: neutral-to-slightly negative; likely minimal share-price effect absent broader context.

United Therapeutics Corp. (UTHR) – Deposito Modulo 144. L'insider a livello direttivo Paul Mahon ha presentato la richiesta di vendere ulteriori 11.000 azioni ordinarie intorno al 24 luglio 2025 tramite Morgan Stanley Smith Barney. Al valore di mercato indicato di 3,35 milioni di dollari, il blocco rappresenta circa il 0,024% delle 45,1 milioni di azioni in circolazione.

Il deposito rivela inoltre cessioni recenti da parte dell'insider per un totale di 66.000 azioni negli ultimi tre mesi, generando 19,56 milioni di dollari di proventi lordi. Includendo la vendita pianificata, le cessioni cumulative di Mahon raggiungerebbero 77.000 azioni, ovvero circa lo 0,17% delle azioni in circolazione. Tutte le azioni derivano da esercizi di stock option pagati in contanti.

Non sono forniti dati finanziari dell'azienda; il documento è esclusivamente una notifica richiesta dalla Regola 144. Sebbene il numero assoluto di azioni sia modesto, la continua vendita da parte degli insider potrebbe attirare l'attenzione degli investitori. Il deposito conferma la conformità normativa e non indica il possesso di informazioni negative non divulgate.

United Therapeutics Corp. (UTHR) – Presentación del Formulario 144. El insider a nivel directivo Paul Mahon ha presentado la solicitud para vender 11,000 acciones comunes adicionales alrededor del 24 de julio de 2025 a través de Morgan Stanley Smith Barney. Al valor de mercado indicado de 3.35 millones de dólares, el bloque representa aproximadamente el 0.024% de las 45.1 millones de acciones en circulación.

La presentación también revela disposiciones recientes de insider que suman 66,000 acciones en los últimos tres meses, generando 19.56 millones de dólares en ingresos brutos. Incluyendo la venta planeada, las disposiciones acumuladas de Mahon alcanzarían 77,000 acciones, o aproximadamente el 0.17% de las acciones en circulación. Todas las acciones provienen de ejercicios de opciones sobre acciones pagados en efectivo.

No se proporcionan estados financieros de la empresa; el documento es estrictamente un aviso requerido por la Regla 144. Aunque el número absoluto de acciones es modesto, la continua venta por parte del insider podría atraer la atención de los inversores. La presentación confirma el cumplimiento regulatorio y no indica la posesión de información adversa no divulgada.

United Therapeutics Corp. (UTHR) – Form 144 제출. 임원급 내부자 Paul Mahon이 Morgan Stanley Smith Barney를 통해 2025년 7월 24일경 추가로 11,000 보통주를 매도할 계획을 제출했습니다. 표시된 시가 총액인 335만 달러 기준으로, 해당 주식 블록은 전체 4,510만 주 중 약 0.024%에 해당합니다.

이 제출서류는 또한 최근 3개월 동안 내부자가 총 66,000주를 처분하여 1,956만 달러의 총 수익을 올린 사실도 공개합니다. 계획된 매도를 포함하면 Mahon의 누적 처분 주식은 77,000주, 즉 발행 주식의 약 0.17%에 달합니다. 모든 주식은 현금으로 결제된 스톡옵션 행사에서 나온 것입니다.

회사 재무정보는 제공되지 않았으며, 이 문서는 규칙 144에 따라 요구되는 통지에 불과합니다. 절대 주식 수는 적지만, 내부자의 지속적인 매도는 투자자의 관심을 끌 수 있습니다. 이 제출은 규제 준수를 확인하며 미공개 불리한 정보 보유를 주장하지 않습니다.

United Therapeutics Corp. (UTHR) – Dépôt du formulaire 144. L'initié de niveau directeur Paul Mahon a déposé une demande pour vendre 11 000 actions ordinaires supplémentaires aux alentours du 24 juillet 2025 via Morgan Stanley Smith Barney. À la valeur marchande indiquée de 3,35 millions de dollars, ce bloc représente environ 0,024 % des 45,1 millions d'actions en circulation.

Le dépôt révèle également des cessions récentes d'initiés totalisant 66 000 actions au cours des trois derniers mois, générant 19,56 millions de dollars de produits bruts. En incluant la vente prévue, les cessions cumulées de Mahon atteindraient 77 000 actions, soit environ 0,17 % des actions en circulation. Toutes les actions proviennent d'exercices d'options sur actions payés en espèces.

Aucun état financier de la société n'est fourni ; le document est strictement un avis requis par la règle 144. Bien que le nombre absolu d'actions soit modeste, la poursuite des ventes d'initiés pourrait attirer l'attention des investisseurs. Le dépôt confirme la conformité réglementaire et ne prétend pas détenir d'informations défavorables non divulguées.

United Therapeutics Corp. (UTHR) – Form 144 Einreichung. Der Insider auf Direktorenebene, Paul Mahon, hat die Anmeldung eingereicht, um zusätzlich 11.000 Stammaktien etwa am 24. Juli 2025 über Morgan Stanley Smith Barney zu verkaufen. Zum angegebenen Marktwert von 3,35 Millionen US-Dollar entspricht dieses Paket etwa 0,024 % der 45,1 Millionen ausstehenden Aktien.

Die Einreichung offenbart auch kürzliche Insider-Veräußerungen von insgesamt 66.000 Aktien in den letzten drei Monaten, die Bruttoerlöse von 19,56 Millionen US-Dollar generierten. Einschließlich des geplanten Verkaufs würden Mahons kumulative Veräußerungen 77.000 Aktien erreichen, was etwa 0,17 % der ausstehenden Aktien entspricht. Alle Aktien stammen aus bar bezahlten Aktienoptionsausübungen.

Es werden keine Unternehmensfinanzdaten bereitgestellt; das Dokument ist ausschließlich eine gemäß Regel 144 erforderliche Mitteilung. Obwohl die absolute Stückzahl gering ist, könnte der fortgesetzte Insider-Verkauf die Aufmerksamkeit der Investoren auf sich ziehen. Die Einreichung bestätigt die Einhaltung der Vorschriften und behauptet nicht, über nicht veröffentlichte nachteilige Informationen zu verfügen.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Eric Li
Signature:/s/ Eric Li
Name/Title:Eric Li (Shufu Li)
Date:07/24/2025
Volvo Car Corporation
Signature:/s/ Hakan Samuelsson
Name/Title:Hakan Samuelsson, Director
Date:07/24/2025
Signature:/s/ Helen Hu
Name/Title:Helen Hu, Director & Authorized Signatory
Date:07/24/2025
PSD Investment Limited
Signature:/s/ Shufu Li
Name/Title:Shufu Li, Sole Director
Date:07/24/2025
PSD Capital Limited
Signature:/s/ Shufu Li
Name/Title:Shufu Li, Sole Director
Date:07/24/2025
Snita Holding B.V.
Signature:/s/ Fredrik Hansson
Name/Title:Fredrik Hansson, Authorized Signatory
Date:07/24/2025
Signature:/s/ Helen Hu
Name/Title:Helen Hu, Director
Date:07/24/2025
Volvo Car AB
Signature:/s/ Hakan Samuelsson
Name/Title:Hakan Samuelsson, Director
Date:07/24/2025
Signature:/s/ Helen Hu
Name/Title:Helen Hu, Authorized Signatory
Date:07/24/2025
Geely Sweden Holdings AB
Signature:/s/ Shufu Li
Name/Title:Shufu Li, Director
Date:07/24/2025
Signature:/s/ Donghui Li
Name/Title:Donghui Li, Director
Date:07/24/2025
Shanghai Geely Zhaoyuan International Investment Co., Ltd
Signature:/s/ Donghui Li
Name/Title:Donghui Li, Director
Date:07/24/2025
Beijing Geely Wanyuan International Investment Co., Ltd
Signature:/s/ Quan Zhang
Name/Title:Quan Zhang, Director
Date:07/24/2025
Beijing Geely Kaisheng International Investment Co., Ltd
Signature:/s/ Quan Zhang
Name/Title:Quan Zhang, Director
Date:07/24/2025
Zhejiang Geely Holding Group Company Limited
Signature:/s/ Donghui Li
Name/Title:Donghui Li, Legal Representative & Director
Date:07/24/2025
Geely Sweden Automative Investment B.V.
Signature:/s/ Per Ansgar
Name/Title:Per Ansgar, Director
Date:07/24/2025
Signature:/s/ Quan Zhang
Name/Title:Quan Zhang, Director
Date:07/24/2025

FAQ

How many United Therapeutics (UTHR) shares are being sold under this Form 144?

11,000 common shares are slated for sale.

What is the estimated market value of the planned UTHR share sale?

Approximately $3.35 million based on the filing’s stated price.

How significant is the sale relative to shares outstanding?

The block equals about 0.024 % of the 45.1 million shares outstanding, a minor portion of float.

Have there been other recent insider sales by the same filer?

Yes. Mahon has already sold 66,000 shares since May 2025, generating roughly $19.56 million in proceeds.

What is the nature of the shares being sold?

All shares originate from stock-option exercises paid for in cash.

Which broker is handling the transaction?

Morgan Stanley Smith Barney LLC, Executive Financial Services desk.
Polestar Automotive Holding UK Ltd

NASDAQ:PSNYW

PSNYW Rankings

PSNYW Latest News

PSNYW Latest SEC Filings

PSNYW Stock Data

338.87M
20.50M
4.19%
Auto Manufacturers
Consumer Cyclical
Link
Sweden
Gothenburg